• Novozymes raised its full-year 2026 organic sales growth outlook to 7%-8% from 5%-7% on stronger performance year-to-date.
• Adjusted EBITDA margin now expected at the high end of the 37%-38% range, reflecting the upgraded sales growth view.
• H1 2026 results scheduled for Aug. 19, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novozymes A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608191139OMX_____CNEWS_EN_GNW1001258380_en) on August 19, 2026, and is solely responsible for the information contained therein.